Antecedent Immunosuppressive Therapy for Immune-Mediated Inflammatory Diseases in the Setting of a COVID-19 Outbreak

• Little is known about the impact of systemic immunosuppressive (IS) medications common to dermatology on COVID-19 risk. • IS for IMID were not associated with increased risk of SARS-CoV-2 infection or severe sequelae, and anti-TNFα monotherapy was associated with decreased admission rate. Pat ients can be reassured continuing these medications during COVID-19.

Source: Journal of the American Academy of Dermatology - July 26, 2020 Category: Dermatology Authors: Jesse Veenstra, Connor R. Buechler, Gabrielle Robinson, Stephanie Chapman, Madeline Adelman, Aaron Tisack, Peter Dimitrion, Erika Todter, Laurie Kohen, Henry W. Lim Source Type: research